ANI Pharmaceuticals Acquires ANDAs from Oakrum Pharma, LLC
August 1, 2022
BAUDETTE, Minn.— July 28, 2022 (BUSINESS WIRE) — ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the purchase of four abbreviated new drug applications (ANDAs) from Oakrum Pharma, LLC, a privately owned biopharmaceutical company.
“We are pleased to expand our generics product portfolio with the acquisition of four limited competition ANDAs. We expect to launch these products and see the value unlock in 2023. This transaction bears further testament to ANI’s strength in business development and complements the significant investment and efforts of our internal research and development team to bring much-needed medicines to patients in need,” stated Nikhil Lalwani, President and Chief Executive Officer of ANI.
“Bourne Partners is excited to announce another successful pharmaceutical transaction. Congratulations to our client, Oakrum, on this transaction with ANI. Bourne Partners remains very active in pharma M&A and financing. Over the past 20 months, Bourne Partners has successfully closed 8 pharma transactions totaling over $500 million in transaction value,” said Managing Director, Jeremy Johnson.
Bourne Partners served as the exclusive financial advisor to Oakrum Pharma, LLC in this transaction and is continuing to work with Oakrum on divesting additional generic pharma assets.
ANI Pharmaceuticals, Inc. is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Our team is focused on delivering sustainable growth by building a successful Purified Cortrophin® Gel franchise, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging our North American manufacturing capabilities. For more information, please visit our website www.anipharmaceuticals.com.
About Bourne Partners
Bourne Partners is a financial services firm specializing in the pharma, pharma services, OTC and consumer health sectors. Located in Charlotte, North Carolina, the company offers investment banking and advisory services. Through Bourne Partners Strategic Capital (“BPSC”), Bourne invests and manages private equity investments in companies within the firm’s core focus areas. As owners and operators with over 20 years of experience, Bourne Partners strives to enrich the lives and improve the health and well-being of their partners and patients across the globe by facilitating the efficient movement of capital through the global healthcare sector. For more information, please visit www.bourne-partners.com.
Source: ANI Pharmaceuticals, Inc.